Rate My Professor Christina Yap

Yap's research specializations encompass adaptive designs, stratified medicine, platform trials including basket and umbrella designs, Bayesian approaches, and incorporating patient-reported outcomes into early phase dose-finding trials. She collaborates with the ICR/Royal Marsden Drug Development Unit, CRUK Centre for Drug Development, Imperial College, and Kings College London, serving as co-principal investigator or co-applicant on over 20 trials from phase I/II to multi-arm multi-stage phase II/III designs. She leads international consensus efforts developing SPIRIT and CONSORT extensions for early phase dose-finding trials. Key publications include 'Adaptive designs in clinical trials: why use them, and how to run and report them' (BMC Medicine, 2018), 'Dose Transition Pathways: The Missing Link Between Complex Dose-Finding Designs and Simple Decision-Making' (Clinical Cancer Research, 2017), 'The Adaptive designs CONSORT Extension (ACE) statement' (BMJ, 2020), and 'CONSORT-DEFINE explanation and elaboration: recommendations for enhancing reporting quality and impact of early phase dose-finding clinical trials' (BMJ, 2025). Yap holds positions such as associate editor for Trials journal, member of the NIHR Statistics Group Steering Committee where she co-leads the Early Phase Clinical Trials Group, MHRA Biologicals & Vaccines Expert Advisory Group member, and Cancer Research UK Clinical Research Committee funding panel member. She has delivered invited talks, organized training courses, and served on data monitoring committees, influencing oncology trial standards globally.